Company Overview
Lantern Pharma Inc. is a biotechnology enterprise dedicated to the discovery and development of oncology drugs, with a specific operational focus on the Indian market. The company operates within the healthcare sector and specifically targets the biotechnology industry, where innovation in therapeutic discovery is central to its business model. As of the latest data, Lantern Pharma Inc. holds a market capitalization of $12.53M and maintains an employee count of 24 individuals. These valuation and staffing figures indicate that the company is a small-cap entity operating with a lean organizational structure, typical for early-stage biotechnology firms that prioritize R&D investment over immediate profitability or large-scale commercial operations. The minimal workforce relative to the market cap suggests a resource-constrained environment where capital allocation is heavily directed toward clinical trial progress rather than general administrative expansion.
Financial Health
The company reports a net income of $-18,920,420 over the trailing twelve months, while its EBITDA stands at $-19,654,380. The gap between the reported revenue, which is unavailable for calculation in this period, and the significant net loss reveals a cost structure dominated by high operational expenses, likely driven by clinical trial costs and R&D expenditures common in the biotech sector. Free cash flow for the period is recorded at $-9,779,377, indicating that the company is burning cash to fund its development pipeline and has not yet achieved positive cash generation. Despite these outflows, the company holds $12.36M in cash, which provides a substantial buffer against its total debt of $93,954. The debt-to-equity ratio is 0.98, suggesting a balanced approach to financing where the company utilizes a mix of equity and debt but maintains a manageable leverage profile for a pre-revenue entity. Furthermore, the current ratio is 3.33, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet immediate obligations. Return on Equity is -104.6% and Return on Assets is -56.0%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than profits, a standard characteristic of companies in the clinical development phase.
Valuation Assessment
Lantern Pharma Inc. does not have a traditional trailing P/E ratio as the P/E Ratio (TTM) is N/A due to negative earnings, while the forward P/E is listed as -0.59. The absence of a positive trailing P/E and the negative forward P/E imply that earnings are currently negative, preventing the application of standard earnings-based valuation multiples until profitability is achieved. The price-to-book ratio is 1.29, indicating that the market values the company at a slight premium over its net book value, reflecting potential intangible assets such as intellectual property and clinical data not fully captured on the balance sheet. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-0.01) suggest that the company cannot be valued on a revenue or cash-flow multiple basis at this time due to lack of revenue and negative EBITDA. The stock has traded with a 52-week high of $5.74 and a 52-week low of $1.11, providing a wide trading range that reflects significant volatility often seen in small-cap biotechnology stocks. The beta value of 1.53 indicates that the stock's price volatility is 53% higher than the broader market, meaning it is expected to move more aggressively than the average market index in response to market-wide shifts.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated significant revenue to calculate year-over-year growth percentages. The lack of revenue growth data implies that the company is still in the investment phase of its lifecycle, focusing on advancing clinical trials for products like LP-300 and LP-184 rather than commercializing revenue-generating products. Regarding income distribution, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This non-dividend status means the company reinvests all available resources, including its cash reserves, back into research, development, and clinical operations to accelerate pipeline progression. Consequently, the overall growth and income profile is characterized by a total reliance on external capital markets and internal cash reserves to fund expansion, with no current mechanism for income distribution to shareholders.